Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study to Assess Clinical and Pivotal Biomarkers in the Urine to Predict the Progression of Nephropathy in Fabry Disease

NCT06065605 is registered in ClinicalTrials.gov with Lysosomal and Rare Disorders Research and Treatment Center, Inc. as lead sponsor.

NCT NCT06065605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06065605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study to Assess Clinical and Pivotal Biomarkers in the Urine to Predict the Progression of Nephropathy in Fabry Disease
Lead sponsor
Lysosomal and Rare Disorders Research and Treatment Center, Inc.
Phase
Observational
Overall status
Unknown status
Start date
September 14, 2023
Completion date
September 12, 2025
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

fabry disease